About
Dr. Douville joined GeneChem in 1997 as a Manager of the Technologies Fund and was promoted to Vice President in 2001 with the raising of their Therapeutics Fund. In 2006, Dr. Douville became General Partner with the raising of their third fund, AgeChem. As of January 2011, Dr. Douville is co-managing the fourth and latest venture fund, AmorChem. Dr. Douville is an active board member of Alethia Biotherapeutics and she was an active member of the boards of directors of Cytochroma Inc., Ambit Biosciences Inc., LymphoSign Inc. and Chronogen Inc. and was also a board member of Idun Pharmaceuticals Inc. before its sale to Pfizer in 2005. Elizabeth obtained her Ph.D. in biochemistry at the University of Ottawa (1994), studying the role of protein tyrosine kinases in oncogenesis. She then received postdoctoral training at the Imperial Cancer Research Fund in London (U.K.) from 1994 to 1997 where she studied oncogenes and their signal transduction pathways. In 2008, Elizabeth obtained a
Position in the VCSift Database
- • 6 investors at GeneChem are tracked.
- • 626 investors hold the General Partner role in VCSift. Elizabeth Douville is one of them.
- • 686 investors are based in Montréal, Quebec, Canada.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Montréal, Canada
Contact Information
Find more investors like Elizabeth
Search Investors